- Home
- EXAS
as 06-20-2025 4:00pm EST
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 10.7B | IPO Year: | N/A |
| Target Price: | $70.68 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.97 - $72.83 | Next Earning Date: | 07-30-2025 |
| Revenue: | $2,828,128,000 | Revenue Growth: | 11.57% |
| Revenue Growth (this year): | 14.58% | Revenue Growth (next year): | 12.75% |
Stock Insider Trading Activity of Exact Sciences Corporation (EXAS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zanotti Katherine S | EXAS | Director | Jun 12 '25 | Sell | $53.20 | 3,207 | $170,612.40 | 72,759 |
Latest Exact Sciences Corporation News
EXAS Breaking Stock News: Dive into EXAS Ticker-Specific Updates for Smart Investing
StockStory
4 days ago
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Turn Down
Simply Wall St.
10 days ago
High Growth Tech Stocks In The US To Watch This June 2025
Zacks
16 days ago
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
Zacks
16 days ago
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
MedTech Dive
17 days ago
Freenome posts pivotal liquid biopsy data as FDA filing nears completion
StockStory
19 days ago
3 Mid-Cap Stocks in the Doghouse
Business Wire
24 days ago
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
Business Wire
25 days ago
Exact Sciences to Participate in June Investor Conference
Compare EXAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXAS Exact Sciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.